ITCI Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.60%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $46,911,949.27

Intra-Cellular Therapies Insider Trading History Chart

Intra-Cellular Therapies Share Price & Price History

^$83.42

▼ -4.21 (-4.80%)

As of 11/15/2024 01:00 AM ET

Days: 30 | 90 | 365

24/7 Automated Profits in Crypto

From Crypto Swap Profits | Ad

What if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast world of passive crypto income, where you set up a dependable income stream that works for you, whether you're at your computer or living your life.

>> Secure Your Spot On The Groundbreaking Workshop Here

Intra-Cellular Therapies Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/12/2024	Michael Halstead	President	Sell	22,869	$89.12	$2,038,085.28
8/30/2024	Sharon Mates	CEO	Sell	34,396	$72.84	$2,505,404.64	1,070,329
8/27/2024	Sharon Mates	CEO	Sell	40,513	$73.58	$2,980,946.54	1,070,329
8/23/2024	Sharon Mates	CEO	Sell	28,680	$74.46	$2,135,512.80	1,070,329
8/21/2024	Sharon Mates	CEO	Sell	53,013	$75.65	$4,010,433.45	1,070,329
8/16/2024	Mark Neumann	EVP	Sell	18,714	$75.08	$1,405,047.12	29,700
6/24/2024	Rory B. Riggs	Director	Sell	4,462	$75.57	$337,193.34	116,600
6/18/2024	Robert L. Van Nostrand	Director	Sell	20,000	$75.91	$1,518,200.00	9,690
3/11/2024	Lawrence J. Hineline	CFO	Sell	10,121	$65.96	$667,581.16
3/11/2024	Michael Halstead	EVP	Sell	7,345	$65.97	$484,549.65	19,803
3/11/2024	Sharon Mates	CEO	Sell	20,565	$65.21	$1,341,043.65	1,050,309
3/7/2024	Lawrence J. Hineline	CFO	Sell	13,132	$66.60	$874,591.20	29,700
3/7/2024	Sharon Mates	CEO	Sell	40,712	$66.50	$2,707,348.00	1,050,309
3/7/2024	Suresh K. Durgam	EVP	Sell	6,450	$66.56	$429,312.00	16,170
2/26/2024	Joel S. Marcus	Director	Sell	26,328	$68.68	$1,808,207.04	39,662
2/26/2024	Lawrence J. Hineline	CFO	Sell	13,337	$69.43	$925,987.91
2/26/2024	Michael Halstead	EVP	Sell	7,907	$69.53	$549,773.71	29,700
2/26/2024	Sharon Mates	CEO	Sell	22,590	$69.79	$1,576,556.10	1,050,309
1/18/2024	Sharon Mates	CEO	Sell	67,917	$65.19	$4,427,509.23	1,050,309
1/16/2024	Sharon Mates	CEO	Sell	75,361	$67.25	$5,068,027.25	1,050,309
1/11/2024	Michael Halstead	EVP	Sell	50,000	$66.83	$3,341,500.00
1/2/2024	Suresh K. Durgam	EVP	Sell	62,282	$70.60	$4,397,109.20
12/13/2023	Suresh K. Durgam	EVP	Sell	21,262	$65.00	$1,382,030.00
11/6/2023	Mark Neumann	EVP	Sell	42,393	$55.63	$2,358,322.59	29,700
9/18/2023	Sharon Mates	CEO	Sell	55,587	$53.76	$2,988,357.12	1,094,722
8/7/2023	Mark Neumann	EVP	Sell	55,300	$58.79	$3,251,087.00	45,339
7/17/2023	Suresh K. Durgam	EVP	Sell	1,842	$65.00	$119,730.00	21,262
6/14/2023	Lawrence J. Hineline	CFO	Sell	81,854	$63.97	$5,236,200.38
4/17/2023	Robert L. Van Nostrand	Director	Sell	10,000	$63.00	$630,000.00	9,345
3/28/2023	Mark Neumann	EVP	Sell	15,604	$54.31	$847,453.24	45,339
3/13/2023	Lawrence J. Hineline	CFO	Sell	5,582	$44.93	$250,799.26
3/13/2023	Sharon Mates	CEO	Sell	20,565	$44.99	$925,219.35	1,130,309
3/13/2023	Suresh K. Durgam	EVP	Sell	7,344	$45.04	$330,773.76	23,104
3/10/2023	Lawrence J. Hineline	CFO	Sell	15,663	$43.06	$674,448.78
3/10/2023	Mark Neumann	EVP	Sell	8,550	$43.34	$370,557.00	57,357
3/10/2023	Sharon Mates	CEO	Sell	41,770	$43.15	$1,802,375.50	1,130,309
3/1/2023	Mark Neumann	EVP	Sell	7,241	$50.01	$362,122.41	49,199
2/24/2023	Lawrence J. Hineline	CFO	Sell	7,455	$47.03	$350,608.65
2/24/2023	Mark Neumann	EVP	Sell	4,046	$47.12	$190,647.52	56,440
2/24/2023	Sharon Mates	CEO	Sell	22,590	$47.03	$1,062,407.70	1,100,309
2/24/2023	Suresh K. Durgam	SVP	Sell	7,906	$47.14	$372,688.84	23,104
2/21/2023	Lawrence J. Hineline	CFO	Sell	10,443	$46.82	$488,941.26
2/21/2023	Mark Neumann	EVP	Sell	3,898	$47.01	$183,244.98	52,580
2/21/2023	Sharon Mates	CEO	Sell	27,848	$46.83	$1,304,121.84	1,100,309
2/21/2023	Suresh K. Durgam	SVP	Sell	8,354	$46.84	$391,301.36	23,104
2/17/2023	Lawrence J. Hineline	CFO	Sell	53,968	$49.83	$2,689,225.44
12/19/2022	Joel S. Marcus	Director	Sell	5,000	$50.82	$254,100.00	29,233
12/13/2022	Sharon Mates	CEO	Sell	33,083	$55.00	$1,819,565.00	1,100,309
12/1/2022	Michael Halstead	EVP	Sell	50,000	$53.73	$2,686,500.00
9/21/2022	Lawrence J. Hineline	CFO	Sell	65,164	$45.63	$2,973,433.32
8/11/2022	Robert L. Van Nostrand	Director	Sell	30,000	$57.13	$1,713,900.00	9,043
5/12/2022	Joel S. Marcus	Director	Sell	10,000	$55.00	$550,000.00	54,233
4/8/2022	Mark Neumann	EVP	Sell	86,348	$64.37	$5,558,220.76	45,339
3/18/2022	Rory B. Riggs	Director	Sell	20,637	$61.18	$1,262,571.66
3/16/2022	Rory B. Riggs	Director	Sell	64,534	$59.27	$3,824,930.18
3/7/2022	Joel S. Marcus	Director	Sell	5,000	$54.52	$272,600.00
3/4/2022	Suresh K. Durgam	Insider	Sell	3,860	$55.52	$214,307.20
3/2/2022	Suresh K. Durgam	Insider	Sell	4,177	$56.98	$238,005.46
2/24/2022	Lawrence J. Hineline	CFO	Sell	7,454	$51.97	$387,384.38
2/24/2022	Mark Neumann	EVP	Sell	7,906	$52.21	$412,772.26
2/24/2022	Sharon Mates	CEO	Sell	22,589	$51.98	$1,174,176.22
2/24/2022	Suresh K. Durgam	Insider	Sell	4,046	$52.27	$211,484.42
2/22/2022	Lawrence J. Hineline	CFO	Sell	10,443	$55.40	$578,542.20
2/22/2022	Mark Neumann	EVP	Sell	11,139	$55.29	$615,875.31
2/22/2022	Sharon Mates	CEO	Sell	27,847	$55.39	$1,542,445.33
2/22/2022	Suresh K. Durgam	Insider	Sell	4,177	$55.29	$230,946.33
1/18/2022	Suresh K. Durgam	Insider	Sell	6,223	$42.03	$261,552.69
1/10/2022	Lawrence J. Hineline	CFO	Sell	19,639	$40.76	$800,485.64
1/10/2022	Mark Neumann	EVP	Sell	20,948	$40.78	$854,259.44
1/10/2022	Sharon Mates	CEO	Sell	41,896	$40.78	$1,708,518.88
1/10/2022	Suresh K. Durgam	Insider	Sell	6,870	$40.76	$280,021.20
12/21/2021	Lawrence J. Hineline	CFO	Sell	175,000	$47.59	$8,328,250.00
12/21/2021	Michael Halstead	EVP	Sell	176,863	$47.56	$8,411,604.28

Missed Nvidia? Watch this ASAP

From Brownstone Research | Ad

This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

SEC Filings (Institutional Ownership Changes) for Intra-Cellular Therapies (NASDAQ:ITCI)

92.33% of Intra-Cellular Therapies stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Intra-Cellular Therapies Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/16/2024	Geode Capital Management LLC	1,708,301	$125.03M	0.0%	+1.3%	1.611%
11/15/2024	M&T Bank Corp	6,163	$0.45M	0.0%	+36.3%	0.006%
11/15/2024	Barclays PLC	34,453	$2.52M	0.0%	+282.0%	0.032%
11/15/2024	Public Employees Retirement System of Ohio	90,529	$6.62M	0.0%	-2.0%	0.085%
11/15/2024	Y Intercept Hong Kong Ltd	13,651	$1M	0.1%	-82.0%	0.013%
11/15/2024	MML Investors Services LLC	3,997	$0.29M	0.0%	-3.2%	0.004%
11/15/2024	Pier Capital LLC	65,560	$4.80M	0.7%	+1.6%	0.062%
11/15/2024	Orion Portfolio Solutions LLC	22,434	$1.64M	0.0%	-5.8%	0.021%
11/15/2024	Castleark Management LLC	51,880	$3.80M	0.2%	-3.5%	0.049%
11/15/2024	Wellington Management Group LLP	1,017,647	$74.46M	0.0%	-18.8%	0.960%
11/15/2024	State Street Corp	1,858,915	$136.02M	0.0%	+3.1%	1.753%
11/15/2024	Quarry LP	1,800	$0.13M	0.0%	+260.0%	0.002%
11/15/2024	Point72 Asset Management L.P.	119,862	$8.77M	0.0%	-78.4%	0.113%
11/15/2024	Parkman Healthcare Partners LLC	241,575	$17.68M	2.3%	+30.6%	0.228%
11/15/2024	Janus Henderson Group PLC	42,729	$3.13M	0.0%	+6.4%	0.040%
11/15/2024	HighTower Advisors LLC	3,829	$0.28M	0.0%	N/A	0.004%
11/15/2024	HighVista Strategies LLC	7,496	$0.55M	0.2%	-69.2%	0.007%
11/15/2024	Holocene Advisors LP	1,370,831	$100.30M	0.4%	-7.4%	1.293%
11/15/2024	Point72 Hong Kong Ltd	6,293	$0.46M	0.0%	-85.8%	0.006%
11/15/2024	Erste Asset Management GmbH	23,400	$1.72M	0.0%	N/A	0.022%
11/15/2024	True Wealth Design LLC	434	$32K	0.0%	N/A	0.000%
11/14/2024	Bellevue Group AG	2,485,627	$181.87M	2.9%	+0.6%	2.344%
11/14/2024	Wasatch Advisors LP	3,848,588	$281.60M	1.4%	+3.5%	3.630%
11/14/2024	Edgestream Partners L.P.	54,629	$4M	0.2%	N/A	0.052%
11/14/2024	PFM Health Sciences LP	77,387	$5.66M	0.3%	-54.6%	0.073%
11/14/2024	Point72 Europe London LLP	19,385	$1.42M	0.1%	-40.0%	0.018%
11/14/2024	Captrust Financial Advisors	8,050	$0.59M	0.0%	+47.0%	0.008%
11/14/2024	Vestal Point Capital LP	30,000	$2.20M	0.2%	N/A	0.028%
11/14/2024	Suvretta Capital Management LLC	1,439,026	$105.29M	3.4%	-8.1%	1.357%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	323,208	$23.65M	0.0%	+3.6%	0.305%
11/14/2024	Zurcher Kantonalbank Zurich Cantonalbank	22,522	$1.65M	0.0%	+13.2%	0.021%
11/14/2024	MetLife Investment Management LLC	6,488	$0.48M	0.0%	-1.9%	0.006%
11/13/2024	Glenmede Trust Co. NA	11,469	$0.84M	0.0%	-10.1%	0.011%
11/13/2024	Cynosure Group LLC	14,442	$1.06M	0.2%	+161.0%	0.014%
11/13/2024	BNP Paribas Financial Markets	24,923	$1.82M	0.0%	-49.9%	0.024%
11/13/2024	FMR LLC	11,121,652	$813.77M	0.0%	-1.0%	10.490%
11/13/2024	The Manufacturers Life Insurance Company	22,057	$1.61M	0.0%	+1.3%	0.021%
11/13/2024	Bank of Montreal Can	64,198	$4.71M	0.0%	-78.1%	0.061%
11/12/2024	Westfield Capital Management Co. LP	1,159,356	$84.83M	0.4%	+11.2%	1.094%
11/12/2024	Algert Global LLC	45,350	$3.32M	0.1%	-31.6%	0.043%
11/12/2024	Cerity Partners LLC	44,107	$3.23M	0.0%	+62.9%	0.042%
11/12/2024	Eagle Asset Management Inc.	624,759	$45.71M	0.2%	+130.5%	0.589%
11/12/2024	HealthInvest Partners AB	84,578	$6.19M	2.9%	+136.0%	0.080%
11/12/2024	Charles Schwab Investment Management Inc.	904,909	$66.21M	0.0%	-1.8%	0.854%
11/8/2024	BNP PARIBAS ASSET MANAGEMENT Holding S.A.	454,538	$33.26M	0.1%	+31.9%	0.429%
11/8/2024	Connor Clark & Lunn Investment Management Ltd.	17,099	$1.25M	0.0%	N/A	0.016%
11/8/2024	Commerce Bank	6,643	$0.49M	0.0%	-2.0%	0.006%
11/8/2024	Avior Wealth Management LLC	4,473	$0.33M	0.0%	+3.0%	0.004%
11/8/2024	B. Metzler seel. Sohn & Co. Holding AG	33,291	$2.44M	0.0%	N/A	0.031%
11/8/2024	Phocas Financial Corp.	19,233	$1.41M	0.0%	-5.9%	0.018%
11/7/2024	Whalen Wealth Management Inc.	2,996	$0.22M	0.2%	N/A	0.003%
11/7/2024	First Turn Management LLC	254,800	$18.64M	3.0%	-26.6%	0.240%
11/7/2024	LMR Partners LLP	31,177	$2.28M	0.0%	+96.2%	0.029%
11/7/2024	Swiss National Bank	185,500	$13.57M	0.0%	+8.1%	0.175%
11/6/2024	Mutual of America Capital Management LLC	44,091	$3.23M	0.0%	-0.9%	0.042%
11/6/2024	Natixis Advisors LLC	24,583	$1.80M	0.0%	-22.4%	0.023%
11/6/2024	Simplify Asset Management Inc.	30,883	$2.26M	0.1%	+66.6%	0.029%
11/6/2024	CIBC Asset Management Inc	2,806	$0.21M	0.0%	N/A	0.003%
11/6/2024	KBC Group NV	2,864	$0.21M	0.0%	+17.3%	0.003%
11/6/2024	Oppenheimer Asset Management Inc.	38,850	$2.84M	0.0%	+9.5%	0.037%
11/6/2024	MQS Management LLC	3,672	$0.27M	0.2%	N/A	0.003%
11/5/2024	Victory Capital Management Inc.	63,742	$4.66M	0.0%	-6.5%	0.060%
11/5/2024	Aigen Investment Management LP	14,890	$1.09M	0.2%	+91.3%	0.014%
11/5/2024	Prime Capital Investment Advisors LLC	7,420	$0.54M	0.0%	-5.0%	0.007%
11/5/2024	Entropy Technologies LP	7,116	$0.52M	0.1%	N/A	0.007%
11/4/2024	Versor Investments LP	3,509	$0.26M	0.0%	N/A	0.003%
11/4/2024	Lisanti Capital Growth LLC	58,115	$4.25M	1.1%	-29.9%	0.055%
11/4/2024	State of New Jersey Common Pension Fund D	35,673	$2.61M	0.0%	+0.6%	0.034%
11/4/2024	TimesSquare Capital Management LLC	438,083	$32.06M	0.5%	+6.5%	0.413%
11/2/2024	Covestor Ltd	1,811	$0.13M	0.1%	+40.4%	0.002%
11/1/2024	Atria Investments Inc	5,137	$0.38M	0.0%	+41.1%	0.005%
11/1/2024	Assetmark Inc.	2,477	$0.18M	0.0%	+9.1%	0.002%
11/1/2024	Capital Performance Advisors LLP	1,012	$74K	0.0%	N/A	0.001%
11/1/2024	Quantum Private Wealth LLC	38,661	$2.83M	1.0%	+1.0%	0.037%
10/31/2024	Principal Financial Group Inc.	597,713	$43.74M	0.0%	+3.3%	0.566%
10/31/2024	M&G PLC	124,324	$9.08M	0.0%	N/A	0.118%
10/29/2024	Emerald Advisers LLC	441,296	$32.29M	1.3%	+12.4%	0.418%
10/29/2024	Harbor Capital Advisors Inc.	34,974	$2.56M	0.1%	+144.6%	0.033%
10/29/2024	Emerald Mutual Fund Advisers Trust	334,673	$24.49M	1.3%	+6.6%	0.317%
10/28/2024	Oak Ridge Investments LLC	11,391	$0.83M	0.1%	-3.8%	0.011%
10/28/2024	US Bancorp DE	7,951	$0.58M	0.0%	+3.3%	0.008%
10/25/2024	Pinnacle Associates Ltd.	176,124	$12.61M	0.2%	+3.0%	0.167%
10/25/2024	China Universal Asset Management Co. Ltd.	20,323	$1.49M	0.2%	+63.9%	0.019%
10/25/2024	abrdn plc	250,963	$18.36M	0.0%	+7.5%	0.238%
10/25/2024	Pallas Capital Advisors LLC	2,990	$0.23M	0.0%	-27.4%	0.003%
10/24/2024	Nisa Investment Advisors LLC	2,676	$0.20M	0.0%	-35.8%	0.003%
10/24/2024	DekaBank Deutsche Girozentrale	51,997	$3.80M	0.0%	-1.0%	0.049%
10/24/2024	Wealth Enhancement Advisory Services LLC	8,810	$0.65M	0.0%	+185.6%	0.008%
10/24/2024	PFG Investments LLC	3,309	$0.24M	0.0%	-62.9%	0.003%
10/23/2024	Mirae Asset Global Investments Co. Ltd.	3,822	$0.28M	0.0%	+21.3%	0.004%
10/23/2024	Assenagon Asset Management S.A.	232,933	$17.04M	0.0%	-32.1%	0.221%
10/23/2024	Moody Aldrich Partners LLC	91,104	$6.67M	1.2%	-8.0%	0.086%
10/23/2024	Hennion & Walsh Asset Management Inc.	14,942	$1.09M	0.1%	-9.5%	0.014%
10/22/2024	Lecap Asset Management Ltd.	6,815	$0.50M	0.1%	N/A	0.006%
10/21/2024	Cetera Trust Company N.A	2,520	$0.18M	0.1%	+24.8%	0.002%
10/19/2024	Allspring Global Investments Holdings LLC	1,855	$0.14M	0.0%	-97.3%	0.002%
10/18/2024	Raymond James & Associates	158,852	$11.62M	0.0%	+2.8%	0.150%
10/16/2024	nVerses Capital LLC	3,900	$0.29M	0.1%	N/A	0.004%
10/11/2024	Creative Planning	16,188	$1.18M	0.0%	-17.5%	0.015%
10/10/2024	Essex Investment Management Co. LLC	58,385	$4.27M	0.7%	+85.7%	0.055%

Data available starting January 2016

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Today's Range

Now: $83.42

$83.21

$87.12

50 Day Range

MA: $78.27

$71.19

$91.57

52 Week Range

Now: $83.42

$54.17

$93.45

Volume

628,100 shs

Average Volume

864,069 shs

Market Capitalization

$8.84 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97

Who are the company insiders with the largest holdings of Intra-Cellular Therapies?: Intra-Cellular Therapies' top insider shareholders include:
Sharon Mates (CEO)
Rory B Riggs (Director)
Mark Neumann (EVP)
Joel S Marcus (Director)
Lawrence J Hineline (CFO)
Michael Halstead (EVP)
Suresh K Durgam (EVP)
Suresh K Durgam (SVP)
Nostrand Robert L Van (Director)
Michael Halstead (President)
Suresh K Durgam (EVP)
Learn More about top insider investors at Intra-Cellular Therapies.
Who are the major institutional investors of Intra-Cellular Therapies?: Intra-Cellular Therapies' top institutional shareholders include:
FMR LLC — 10.49%
Wasatch Advisors LP — 3.63%
Bellevue Group AG — 2.34%
State Street Corp — 1.75%
Geode Capital Management LLC — 1.61%
Suvretta Capital Management LLC — 1.36%
Learn More about top institutional investors of Intra-Cellular Therapies stock.
Which institutional investors are selling Intra-Cellular Therapies stock?: In the previous quarter, ITCI stock was sold by these institutional investors:
Point72 Asset Management L.P.
Wellington Management Group LLP
Bank of Montreal Can
Suvretta Capital Management LLC
FMR LLC
Assenagon Asset Management S.A.
Holocene Advisors LP
PFM Health Sciences LP
During the last year, company insiders that have sold Intra-Cellular Therapies company stock include:
Sharon Mates (CEO)
Rory B Riggs (Director)
Mark Neumann (EVP)
Joel S Marcus (Director)
Lawrence J Hineline (CFO)
Michael Halstead (EVP)
Suresh K Durgam (EVP)
Suresh K Durgam (SVP)
Nostrand Robert L Van (Director)
Michael Halstead (President)
Learn More investors selling Intra-Cellular Therapies stock.
Which institutional investors are buying Intra-Cellular Therapies stock?: During the last quarter, ITCI stock was acquired by institutional investors including:
Eagle Asset Management Inc.
Wasatch Advisors LP
M&G PLC
Westfield Capital Management Co. LP
BNP PARIBAS ASSET MANAGEMENT Holding S.A.
State Street Corp
Parkman Healthcare Partners LLC
Edgestream Partners L.P.